Combination treatment for high-risk acute myeloid leukemia patients undergoing transplant

A Phase 1 Study of Venetoclax in Combination With Azacitidine (VEN/AZA) Followed by Donor Lymphocyte Infusion (DLI) for Patients With Very High-Risk Acute Myeloid Leukemia (AML) Undergoing Allogeneic Hematopoietic Cell Transplant (HCT)

This study is testing a new combination treatment for people with very high-risk acute myeloid leukemia who are getting a stem cell transplant to see if it helps prevent the cancer from coming back.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 25 (estimated)
• Ages: 18 Years to 75 Years
• Sex: All
• Sponsor: University of Miami (Academic / other)
• Locations: 1 site (Miami, Florida)
• Trial ID: NCT06158100 on ClinicalTrials.gov

What this trial studies

This study investigates the effects of a combination treatment involving venetoclax, azacitidine, and donor lymphocyte infusion (DLI) in patients with very high-risk acute myeloid leukemia (AML) who are undergoing allogeneic hematopoietic cell transplantation. The goal is to assess the tolerability of this treatment and its effectiveness in preventing disease relapse after the transplant. Participants will be closely monitored for measurable residual disease and overall recovery post-transplant.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18-75 with very high-risk AML in morphological remission prior to transplant.

Not a fit: Patients with low-risk AML or those not in morphological remission prior to transplant may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly reduce the risk of relapse in high-risk AML patients after transplantation.

How similar studies have performed: Other studies have shown promising results with similar combination therapies in high-risk AML, suggesting potential for success in this approach.

Eligibility criteria

Inclusion Criteria:

1. Male and female patients between the ages of 18-75.
2. Patients with a histologic diagnosis of AML in morphological remission (\<5% bone marrow (BM) blasts) prior to allogeneic hematopoietic cell transplantation and very high-risk for relapse defined as: (i) Presence of measurable residual disease (MRD) by multicolor flow cytometry (MFC) prior to transplant and receiving a reduced intensity conditioning (RIC) or nonmyeloablative (NMA) regimen (ii) Presence of MRD by MFC at day +30 post-transplant (iii) All patients with monosomal karyotype (MK) and those with 17p/tumor protein p53 (TP53) mutated disease irrespective of MRD status and intensity of conditioning regimen.
3. Adequate hematopoietic recovery after HCT, defined as:

   * Absolute neutrophil count (ANC) \>= 1 x 10\^9/L without daily use of myeloid growth factors
   * Platelet count \>= 50 x 10\^9/L without platelet transfusion within 1 week
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
5. Serum creatinine =\< 1.5 mg/dL or creatinine clearance greater or equal than 40 cc/min
6. Serum bilirubin =\< 1.5 x upper limit of normal (ULN)
7. Aspartate transaminase (AST) or alanine transaminase (ALT) =\< 2.5 x ULN
8. Alkaline phosphatase =\< 2.5 x UL
9. Negative serum or urine pregnancy test for women with reproductive potential.
10. A negative donor-specific antibody (DSA) assay (i.e., Micro-Flow Imaging (MFI) \<m3000) for recipients of any mismatched graft (including haploidentical) HCT.

Exclusion Criteria:

1. Active disease (\>5% blasts or any evidence of extra-medullary disease) at the time of transplantation or at day +30
2. Active acute graft-versus-host disease (aGVHD) requiring systemic IST or history of aGVHD grade III or higher.
3. Active chronic GVHD requiring systemic immunosuppressive therapy (IST).
4. Active uncontrolled systemic fungal, bacterial, or viral infection
5. Known active viral infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV)
6. Significant active cardiac disease within the previous 6 months, including: New York Heart Association (NYHA) class III or IV congestive heart failure. Unstable angina, angina requiring surgical or medical intervention, and/or myocardial infarction.
7. History of any other malignancy within 2 years prior to study entry, except for: adequately treated in situ carcinoma of the cervix or carcinoma in situ of breast; basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin; previous malignancy confined and surgically resected (or treated with other modalities) with curative intent; myelodysplastic syndrome.

Where this trial is running

Miami, Florida

• University of Miami — Miami, Florida, United States (Recruiting)

Study contacts

• Principal investigator: Antonio M Jimenez Jimenez, MD — University of Miami
• Study coordinator: Antonio M Jimenez Jimenez, MD

Conditions Acute Myeloid Leukemia; Hematopoietic Cell Transplant